Oncology · Hepatocellular CarcinomaOtherclinicalmid-term

CENPI identified as a promoter of hepatocellular carcinoma progression via PI3K/AKT/mTOR pathway

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/5/2026, 12:34:09 AM

Assessment confidence: 92% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The identification of CENPI as a promoter of HCC progression highlights a potential new therapeutic target that could reshape treatment strategies in oncology. Monitoring ongoing research could provide insights into novel interventions that may enhance patient outcomes in a challenging therapeutic area. Regulatory context from FDA (FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients) supports the near-term read. Assessment grounded in 6 ranked evidence items (6 high-relevance).

Strategic Assessment

The strongest clinical anchor is A Trial of SHR-8068 Combined With Adebrelimab and Apatinib in Perioperative Treatment of Resectable Hepatocellular Carcinoma (ClinicalTrials.gov), sub-indication match (liver cancer). If CENPI is validated as a therapeutic target, it could lead to the development of new treatments, potentially increasing market share for companies that invest in this area.

Competitive Pressure

The most relevant competitive pressure comes from Understanding CENPI's role in HCC may reveal new therapeutic targets, impacting current treatment strategies..

Regulatory Outlook

Regulatory risk is concentrated around The exploration of CENPI as a biomarker or therapeutic target may necessitate new regulatory pathways for approval, impacting timelines for bringing new therapies to market..

Key Risks

Elevated medium regulatory exposure for CENPI could delay market entry or constrain labeling if agency review intensifies.
Evidence gap: no medium- or high-relevance regulatory precedents in ingested corpus.

Key Opportunities

If CENPI is validated as a therapeutic target, it could lead to the development of new treatments, potentially increasing market share for companies that invest in this area.
Percutaneous thermal ablation is used to treat early-stage, non-resectable hepatocellular carcinoma (HCC). NK-cell immunotherapy has been studied as an adjuvant treatment, but the efficacy remains unclear when combined with ablation.
Exploring CENPI as a potential biomarker or therapeutic target in HCC.

What Would Change This Assessment

This becomes more urgent if Monitor further research on CENPI's mechanisms and potential therapeutic interventions targeting this pathway.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Update on the PATHWAYS clinical trial
MHRAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

A Trial of SHR-8068 Combined With Adebrelimab and Apatinib in Perioperative Treatment of Resectable Hepatocellular Carcinoma
ClinicalTrials.govhigh relevance
Sub-indication match (liver cancer)
FDA document
View source
A Clinical Trial of Neoadjuvant Targeted Therapy, Immunotherapy, and Lysogenic HSV-Based Virotherapy in Resectable Head and Neck Squamous Cell Carcinoma
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
A Study of Belantamab Mafodotin Monotherapy in Multiple Myeloma Participants With Normal and Varying Degree of Impaired Renal Function
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Hyperthermic Intraperitoneal Chemotherapy With Cisplatin and Paclitaxel for Gastric Cancer at High Risk of Peritoneal Recurrence
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma
ClinicalTrials.govlow relevance
Broad oncology match without sub-indication specificity
FDA document
View source
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
ClinicalTrials.govlow relevance
Broad oncology match without sub-indication specificity
FDA document
View source

LTβR as Novel Target for Cancer Immunotherapy: Mechanisms and Therapeutic Potential
Humanexa Signalslow relevance
Broad oncology match without sub-indication specificity

Centromere protein I promotes hepatocellular carcinoma progression by activating PI3K/AKT/mTOR-CDK2 cascade.
PubMedhigh relevance
Sub-indication match (liver cancer); Entity match (cenpi)
FDA document
View source
MAGED4 promotes hepatocellular carcinoma progression via activation of JAK2/STAT3 pathway by stabilizing TRIM21.
PubMedhigh relevance
Sub-indication match (liver cancer); Entity match (hepatocellular carcinoma hcc )
FDA document
View source
Dual-ligand-modified cantharidin nanoparticles for the treatment of hepatocellular carcinoma via the inhibition of Ephb4.
PubMedhigh relevance
Sub-indication match (liver cancer); Entity match (hepatocellular carcinoma hcc )
FDA document
View source
ABHD17C regulates the efficacy of lenvatinib in suppressing hepatocellular carcinoma.
PubMedhigh relevance
Sub-indication match (liver cancer); Entity match (hepatocellular carcinoma hcc )
FDA document
View source
High-Intensity thermal stress enhances adoptive NK-cell cytotoxicity in poorly differentiated hepatocellular carcinoma.
PubMedhigh relevance
Sub-indication match (liver cancer); Entity match (hepatocellular carcinoma hcc )
FDA document
View source
UBE2C promotes pancreatic cancer progression through PI3K/Akt/mTOR signaling pathway.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Sequential axitinib and survivin vaccination unlock curative PD-1 immunotherapy in renal carcinoma.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

CENPI
hepatocellular carcinoma (HCC)
oncology therapeutics

Commercial impact

medium

If CENPI is validated as a therapeutic target, it could lead to the development of new treatments, potentially increasing market share for companies that invest in this area.

Regulatory impact

medium

The exploration of CENPI as a biomarker or therapeutic target may necessitate new regulatory pathways for approval, impacting timelines for bringing new therapies to market.

What to watch

Monitor further research on CENPI's mechanisms and potential therapeutic interventions targeting this pathway.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.